--- title: "Evaxion (EVAX) news: delisting and offering" url: "https://aibio.space/companies/evaxion/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "EVAX delisting and offering news: Nasdaq withdraws Evaxion Biotech (now Evaxion A/S) delisting determination. Evaxion A/S (NASDAQ: EVAX), Denmark." --- EVAX Evaxion A/S NASDAQ · Denmark # Evaxion (EVAX) news EVAX delisting and offering news Financings · 2026-03-05 ## [Evaxion says cash funds operations into second half of 2027](https://aibio.space/news/evaxion-says-cash-funds-operations-second-half-2027/) Evaxion says its cash can fund operations into the second half of 2027, after a $7.5 million option exercise fee and a debt conversion with the European Investment Bank. The release reports a cash burn of about $14 million for 2026 and names no bank or agent for its amended at-the-market facility. ## Latest Evaxion news 1. 2025-12-10 Financings [Evaxion registers up to $45,527,824 in ADS sales after public float passes $75.0 million](https://aibio.space/news/evaxion-registers-up-45-527-824-ads-sales-after-public-float-passes-75/) Evaxion says its public float now passes $75.0 million, which lifts a sales cap and allows up to $45.52 million more in ADS sales through JonesTrading. The float figure uses an October share price, and the stock was $6.28 in early December. 2. 2025-02-14 Listings [Nasdaq withdraws Evaxion Biotech (now Evaxion A/S) delisting determination](https://aibio.space/news/nasdaq-withdraws-evaxion-biotech-now-evaxion-s-delisting-determination/) Evaxion says it restored stockholders' equity above the $2.5 million minimum and has cash runway into mid-2026. Nasdaq imposed a one-year monitor. 3. 2025-01-14 Listings [Evaxion Biotech (now Evaxion A/S) completes ADS ratio change, like a 1-for-5 split](https://aibio.space/news/evaxion-biotech-now-evaxion-s-completes-ads-ratio-change-like-1-5/) Each ADS now represents fifty ordinary shares instead of ten. The company says the change is meant to support liquidity in its ADSs on Nasdaq. ## Evaxion at a glance - **Ticker**: EVAX - **Listing**: NASDAQ - **Country**: Denmark - **Cash, Dec 31, 2025**: $23.2 million ### Related companies - [Saniona AB](https://aibio.space/companies/saniona/) OMXSTO: SANION - [Bavarian Nordic](https://aibio.space/companies/bavarian-nordic/) OMXCOP: BAVA - [Genmab](https://aibio.space/companies/genmab/) OMXCOP: GMAB - [ExpreS2ion Biotech Holding AB](https://aibio.space/companies/expres2ion-biotech/) OMXSTO: EXPRS2 - [Zealand Pharma](https://aibio.space/companies/zealand-pharma/) OMXCOP: ZEAL - [Pharma Equity Group](https://aibio.space/companies/pharma-equity/) OMXCOP: PEG - [H. Lundbeck](https://aibio.space/companies/h-lundbeck/) OMXCOP: HLUN_A - [Strategic Partners](https://aibio.space/companies/strategic-partners/) OMXCOP: STRAP ### Also on NASDAQ - [PMV Pharmaceuticals](https://aibio.space/companies/pmv-pharmaceuticals/) PMVP - [Definium Therapeutics](https://aibio.space/companies/definium-therapeutics/) DFTX - [OneMedNet](https://aibio.space/companies/onemednet/) ONMD - [Cartesian Therapeutics](https://aibio.space/companies/cartesian-therapeutics/) RNAC - [Genenta Science S.p.A.](https://aibio.space/companies/genenta-science-s-p-a/) GNTA - [InMode](https://aibio.space/companies/inmode/) INMD ## What Evaxion does Evaxion A/S is a TechBio company that uses its AI-Immunology platform to develop vaccines for cancer and infectious diseases, and it plans to expand into autoimmune diseases. The company says the platform has been developed over 18 years, can be scaled to more than 100 different diseases, and works with different vaccine modalities. Its most advanced cancer vaccine, EVX-01, targets neoantigens and is being evaluated as a treatment for advanced melanoma. The company says 81% of the vaccine neoantigen targets in EVX-01 trigger a tumor-specific immune response. Its EVX-03 and EVX-04 candidates target endogenous retrovirus tumor antigens for precision cancer vaccines. For infectious diseases, the pipeline includes vaccines against pathogens for which no vaccines exist today, including S. aureus, Group A streptococcus, N. gonorrhoeae and cytomegalovirus. Its gonorrhoea candidate, EVX-B2, has achieved preclinical Proof of Concept and shows strong efficacy against 50 clinically relevant bacteria strains. Evaxion is a Danish company that began operations in August 2008, and its ADSs trade on the Nasdaq Capital Market under the symbol EVAX. | Product or program | What it is | Stage | |---|---|---| | AI-Immunology platform | AI platform for identifying vaccine targets and suggesting vaccine designs | | | EVX-01 | Cancer vaccine targeting neoantigens, evaluated for advanced melanoma | being evaluated as a treatment for advanced melanoma | | EVX-03 and EVX-04 | Cancer vaccine candidates targeting endogenous retrovirus tumor antigens | | | EVX-B2 | Gonorrhoea vaccine candidate with broad coverage of clinical strains | preclinical Proof of Concept | Summarised from the company's [20-F filed Mar 5, 2026](https://www.sec.gov/Archives/edgar/data/1828253/000117184326001346/evax20251231_20f.htm). ## Evaxion annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$7.5 million](https://www.sec.gov/Archives/edgar/data/1828253/000117184326001346/) | [$3.3 million](https://www.sec.gov/Archives/edgar/data/1828253/000117184326001346/) | | Research and development | [$10.0 million](https://www.sec.gov/Archives/edgar/data/1828253/000117184326001346/) | [$10.5 million](https://www.sec.gov/Archives/edgar/data/1828253/000117184326001346/) | | Net income (loss) | [-$7.7 million](https://www.sec.gov/Archives/edgar/data/1828253/000117184326001346/) | [-$10.6 million](https://www.sec.gov/Archives/edgar/data/1828253/000117184326001346/) | | Cash from operations | [-$6.6 million](https://www.sec.gov/Archives/edgar/data/1828253/000117184326001346/) | [-$12.9 million](https://www.sec.gov/Archives/edgar/data/1828253/000117184326001346/) | | Cash and equivalents | [$23.2 million](https://www.sec.gov/Archives/edgar/data/1828253/000117184326001346/) | [$6.0 million](https://www.sec.gov/Archives/edgar/data/1828253/000117184326001346/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $23.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Evaxion Was Evaxion delisted? Our latest story on this, dated Feb 14, 2025: "Nasdaq withdraws Evaxion Biotech (now Evaxion A/S) delisting determination". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nasdaq-withdraws-evaxion-biotech-now-evaxion-s-delisting-determination/). Has Evaxion raised money recently? Our latest story on this, dated Mar 5, 2026: "Evaxion says cash funds operations into second half of 2027". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/evaxion-says-cash-funds-operations-second-half-2027/). What is the ticker symbol of Evaxion? Evaxion A/S trades under the ticker EVAX on NASDAQ. Where is Evaxion listed? Evaxion A/S is listed on NASDAQ. What is the SEC CIK of Evaxion? The SEC Central Index Key (CIK) for Evaxion A/S is 1828253. Its filings are on SEC EDGAR. How many shares does Evaxion have outstanding? 417,010,756 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-05. Which country or territory is Evaxion listed under? Our directory records Evaxion A/S under Denmark. What does Evaxion do? Our directory classifies Evaxion A/S as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Evaxion? The ISIN recorded for Evaxion A/S is US29970R3030. Does aibio.space cover Evaxion? aibio.space lists Evaxion A/S among 2,820 public biotech companies and publishes its news here as stories appear. Where is Evaxion incorporated? SEC records list its state or country of incorporation as G7. What does Evaxion develop? Evaxion A/S is a TechBio company that uses its AI-Immunology platform to develop vaccines for cancer and infectious diseases, and it plans to expand into autoimmune diseases. The company says the platform has been developed over 18 years, can be scaled to more than 100 different diseases, and works with different vaccine modalities. What is AI-Immunology platform from Evaxion? AI-Immunology platform: AI platform for identifying vaccine targets and suggesting vaccine designs What is EVX-01 from Evaxion? EVX-01: Cancer vaccine targeting neoantigens, evaluated for advanced melanoma Stage: being evaluated as a treatment for advanced melanoma. What was Evaxion's revenue last year? $7.5 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: Evaxion Members talk about Evaxion (EVAX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Evaxion, newest first. Each line links the filing it comes from. 1. 2026-03-05 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1828253/000117184326001348/exh_991.htm) 2. 2025-12-10 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1828253/000110465925119854/tm2533081d2_424b5.htm) 3. 2025-10-17 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1828253/000117184325006501/f6k_101725.htm) 4. 2025-03-26 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1828253/000110465925028218/tm258932-4_424b5.htm) 5. 2025-02-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1828253/000117184325000847/exh_991.htm) 6. 2025-01-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1828253/000117184325000460/exh_991.htm) 7. 2025-01-27 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1828253/000117184325000423/f6k_012725.htm) 8. 2025-01-14 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1828253/000117184325000246/exh_991.htm) 9. 2025-01-10 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1828253/000117184325000156/exh_991.htm) 10. 2024-12-30 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1828253/000117184324007100/exh_991.htm) 11. 2024-11-13 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1828253/000117184324006313/f6k_111224.htm) 12. 2024-11-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1828253/000117184324006317/exh_991.htm) 13. 2024-10-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1828253/000117184324005932/exh_991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:EVAX on TradingView](https://www.tradingview.com/symbols/NASDAQ-EVAX/). ## SEC filings and registration - **SEC name**: Evaxion A/S - **CIK**: 1828253 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: EVAX (Nasdaq) - **State or country of incorporation**: G7 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Emerging growth company - **Business address**: DR NEERGAARDS VEJ 5F, HOERSHOLM - **Phone**: 4552656554 - **Shares outstanding**: 417,010,756 as of 2025-12-31 (20-F filed 2026-03-05) - **Former names**: Evaxion Biotech A/S ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1828253/000117184326006678/f6k_101926.htm) filed 2026-10-19 - [6-K](https://www.sec.gov/Archives/edgar/data/1828253/000117184326006353/f6k_100226.htm) filed 2026-10-02 - [6-K](https://www.sec.gov/Archives/edgar/data/1828253/000117184326006028/f6k_091426.htm) filed 2026-09-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1828253/000117184326005887/f6k_090426.htm) filed 2026-09-04 - [6-K](https://www.sec.gov/Archives/edgar/data/1828253/000117184326005672/f6k_082026.htm) filed 2026-08-20 - [6-K](https://www.sec.gov/Archives/edgar/data/1828253/000117184326005671/evax20260819_6k.htm) filed 2026-08-20 - [6-K](https://www.sec.gov/Archives/edgar/data/1828253/000117184326005577/f6k_081726.htm) filed 2026-08-17 - [6-K](https://www.sec.gov/Archives/edgar/data/1828253/000117184326005527/f6k_073026.htm) filed 2026-08-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001828253), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Evaxion A/S is a public biotech or pharmaceutical company listed on NASDAQ under the ticker EVAX, recorded under Denmark. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Evaxion A/S - **Ticker**: EVAX - **Listing**: NASDAQ - **Country or territory**: Denmark - **Business scope**: Biotechnology - **ISIN**: US29970R3030 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-EVAX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/evaxion/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Evaxion (EVAX) news: delisting and offering", 2026-10-31, https://aibio.space/companies/evaxion/